Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084154 | 0.98 | HTR1A (1.00) | HTR1AHTR7KCNH2 | |
| SCHEMBL7986148 | 0.97 | HTR1A (1.00) | HTR1AHTR7 | |
| SCHEMBL3026254 | 0.91 | HTR1A (0.83) | HTR1A | |
| SCHEMBL11631929 | 0.89 | HTR7 (0.82) | HTR1AHTR7 | |
| SCHEMBL14028451 | 0.89 | HTR1A (0.79) | HTR1A | |
| SCHEMBL21802068 | 0.89 | HTR1A (0.80) | HTR1AHTR7 | |
| SCHEMBL12124719 | 0.89 | HTR1A (0.80) | HTR1A | |
| SCHEMBL11838777 | 0.88 | HTR7 (0.84) | HTR1AHTR7 | |
| SCHEMBL11837243 | 0.88 | HTR7 (0.84) | HTR1AHTR7 | |
| SCHEMBL9377848 | 0.88 | HTR1A (0.77) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
| US-8227604-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | WAYNE STATE UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-7723519-B2 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| US-6982332-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | WAYNE STATE UNIVERSITY | 2003-10-16 | — | — | US | disclosed |
| WO-2002098367-A2 | HYBRID 2-AMINOTETRALIN AND ARYL-SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE IN ALTERING CNS ACTIVITY | WAYNE STATE UNIVERSITY (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | HTR1A 66/4885HTR7 119/4885KCNH2 1015/4885 |
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | HTR3A, HTR3C, HTR2C | HTR1A 18/4885HTR7 9/4885KCNH2 1208/4885 |
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | HTR1A 3/4885HTR7 19/4885KCNH2 1223/4885 |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | HTR3A, HTR3C, HTR2C | HTR1A 17/4885HTR7 9/4885KCNH2 1204/4885 |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | HTR1A 14/4885HTR7 184/4885KCNH2 839/4885 |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | HTR3A, DRD3, DRD2 | HTR1A 46/4885HTR7 10/4885KCNH2 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.